Sivik Global Healthcare LLC Raises Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Sivik Global Healthcare LLC grew its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,500 shares of the pharmaceutical company’s stock after buying an additional 40 shares during the quarter. Vertex Pharmaceuticals accounts for approximately 2.1% of Sivik Global Healthcare LLC’s holdings, making the stock its 29th biggest holding. Sivik Global Healthcare LLC’s holdings in Vertex Pharmaceuticals were worth $5,086,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of VRTX. abrdn plc lifted its position in shares of Vertex Pharmaceuticals by 196.0% during the fourth quarter. abrdn plc now owns 581,018 shares of the pharmaceutical company’s stock worth $236,410,000 after purchasing an additional 384,730 shares during the last quarter. BSN CAPITAL PARTNERS Ltd bought a new stake in Vertex Pharmaceuticals during the 4th quarter valued at about $81,378,000. Jennison Associates LLC boosted its position in Vertex Pharmaceuticals by 3.9% in the 4th quarter. Jennison Associates LLC now owns 3,944,913 shares of the pharmaceutical company’s stock valued at $1,605,146,000 after buying an additional 147,248 shares during the period. Northern Trust Corp grew its stake in Vertex Pharmaceuticals by 4.9% in the 3rd quarter. Northern Trust Corp now owns 2,813,563 shares of the pharmaceutical company’s stock worth $978,388,000 after acquiring an additional 131,539 shares in the last quarter. Finally, International Assets Investment Management LLC increased its position in shares of Vertex Pharmaceuticals by 21,750.1% during the fourth quarter. International Assets Investment Management LLC now owns 115,150 shares of the pharmaceutical company’s stock worth $46,853,000 after acquiring an additional 114,623 shares during the period. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Trading Down 0.9 %

Shares of VRTX traded down $3.39 during midday trading on Tuesday, reaching $392.81. The company had a trading volume of 1,727,899 shares, compared to its average volume of 1,226,496. The firm has a 50 day simple moving average of $410.52 and a 200-day simple moving average of $399.52. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02. The stock has a market cap of $101.53 billion, a PE ratio of 28.28, a price-to-earnings-growth ratio of 1.87 and a beta of 0.35. Vertex Pharmaceuticals Incorporated has a 1-year low of $320.01 and a 1-year high of $448.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 EPS for the quarter, beating analysts’ consensus estimates of $3.85 by $0.35. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. The firm had revenue of $2.52 billion for the quarter, compared to analysts’ expectations of $2.50 billion. During the same period in the prior year, the firm posted $3.33 earnings per share. Research analysts forecast that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current fiscal year.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 354 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $425.70, for a total value of $150,697.80. Following the completion of the transaction, the executive vice president now owns 55,804 shares in the company, valued at $23,755,762.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, COO Stuart A. Arbuckle sold 4,295 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the completion of the sale, the chief operating officer now owns 75,718 shares in the company, valued at approximately $31,819,732.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Ourania Tatsis sold 354 shares of the firm’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the transaction, the executive vice president now directly owns 55,804 shares in the company, valued at approximately $23,755,762.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,381 shares of company stock valued at $5,203,249. Corporate insiders own 0.20% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on VRTX shares. Canaccord Genuity Group reaffirmed a “sell” rating and issued a $371.00 price target on shares of Vertex Pharmaceuticals in a research report on Friday, April 12th. Evercore ISI raised shares of Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 price objective on the stock in a research report on Thursday, April 11th. UBS Group decreased their target price on shares of Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating for the company in a research report on Wednesday, April 17th. Maxim Group lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Finally, Wells Fargo & Company increased their price objective on Vertex Pharmaceuticals from $500.00 to $540.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $429.45.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.